Difference between revisions of "Anakinra (Kineret)"
Jump to navigation
Jump to search
m |
m |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Recombinant IL-1 receptor antagonist | Recombinant IL-1 receptor antagonist | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Castleman disease]] | ||
==Also known as== | ==Also known as== | ||
| Line 6: | Line 9: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
| + | |||
| + | [[Category:IL-1R antagonists]] | ||
| + | [[Category:Recombinant medications]] | ||
| + | |||
| + | [[Category:Castleman disease medications]] | ||
[[Category:FDA approved in 2001]] | [[Category:FDA approved in 2001]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Latest revision as of 14:33, 28 February 2024
Recombinant IL-1 receptor antagonist
Diseases for which it is used
Also known as
- Brand name: Kineret